Elena Reddi

Prof. Elena Reddi

Department of Biology, University of Padova, 35121 Padova, Italy.
orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2016 in Journal of Photochemistry and Photobiology B: Biology
Verified
Journal Article
Closed access
EGElisa Gaio
Elisa Gaio
DSDietrich Scheglmann
Dietrich Scheglmann
ERElena Reddi
Elena Reddi
FMFrancesca Moret
Francesca Moret

1 February 2010 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Closed access
RDRyan Dosselli
Ryan Dosselli
MGMarina Gobbo
Marina Gobbo
EBErika Bolognini
Erika Bolognini
SCSandro Campestrini
Sandro Campestrini
ERElena Reddi
Elena Reddi

5 February 2014 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
RDRyan Dosselli
Ryan Dosselli
RRRubén Ruiz-González
Rubén Ruiz-González
FMFrancesca Moret
Francesca Moret
VAValentina Agnolon
Valentina Agnolon
CCChiara Compagnin
Chiara Compagnin
ERElena Reddi
Elena Reddi

23 January 2020 in Cancers
Verified
Journal Article
Open access
PDF file
EGElisa Gaio
Elisa Gaio
claudia conteclaudia conte
claudia conte
DEDiletta Esposito
Diletta Esposito
ERElena Reddi
Elena Reddi
Fabiana QuagliaFabiana Quaglia
Fabiana Quaglia
FMFrancesca Moret
Francesca Moret
The presence of rare but highly tumorigenic cancer stem cells (CSCs) within the tumors is recognized as one of the major reasons of failure of conventional chemotherapies, mainly attributed to the development of drug resistance and increasing metastatic potential. Here, we propose a therapeutic strategy based on the simultaneous delivery of docetaxel (DTX) and the photosensitizer meso-tetraphenyl chlorine disulfonate (TPCS2a) using hyaluronic acid (HA) coated polymeric nanoparticles (HA-NPs) for the targeting and killing of CD44 over-expressing breast cancer (BC) cells, both differentiated and CSCs (CD44high/CD24low population), thus combining chemotherapy and photodynamic therapy (PDT). Using the CD44high MDA-MB-231 and the CD44low MCF-7 cells, we demonstrated the occurrence of CD44-mediated uptake of HA-NPs both in monolayers and mammosphere cultures enriched in CSCs. Cell treatments showed that combination therapy using co-loaded NPs (HA@DTX/TPCS2a-NPs) had superior efficacy over monotherapies (HA@DTX-NPs or HA@TPCS2a-NPs) in reducing the self-renewal capacity, measured as mammosphere formation efficiency, and in eradicating the CSC population evaluated with aldehyde dehydrogenase activity assay and CD44/CD24 immunostaining. In summary, these in vitro studies demonstrated for the first time the potential of the combination of DTX-chemotherapy and TPCS2a-PDT for killing CSCs using properly designed NPs.

17 January 2013
Verified
Journal Article
Closed access
PDF file
FMFrancesca Moret
Francesca Moret
DSDietrich Scheglmann
Dietrich Scheglmann
ERElena Reddi
Elena Reddi
The folate receptor (FR) is over-expressed in many human tumours and is being intensively studied also in the field of nanomedicine as a target to enhance the selectivity of drug delivery to cancer cells by using nanocarriers bearing folic acid (FA) on their surface. In this study we report the encapsulation of the photosensitizer (PS) meta-tetra(hydroxyphenyl)chlorin (m-THPC) in FA-targeted PEGylated liposomes used as a novel drug delivery system for photodynamic therapy (PDT) of cancer. Our in vitro investigations revealed that only a modest fraction of targeted liposomes were internalized by specific endocytosis in FR-positive KB cells. However, FA-liposomes doubled the uptake of the entrapped m-THPC with respect to un-targeted liposomes and enhanced the photo-induced cytotoxicity in KB cells. In contrast, in FR-negative A549 cells FA-targeted or un-targeted liposomes exhibited a very similar extent of internalization and as a consequence the same photo-killing efficiency.

14 September 2022 in Cancers
Verified
Journal Article
Open access
PDF file
LMLuca Menilli
Luca Menilli
CMCeleste Milani
Celeste Milani
ERElena Reddi
Elena Reddi
FMFrancesca Moret
Francesca Moret
The widespread diffusion of photodynamic therapy (PDT) as a clinical treatment for solid tumors is mainly limited by the patient’s adverse reaction (skin photosensivity), insufficient light penetration in deeply seated neoplastic lesions, unfavorable photosensitizers (PSs) biodistribution, and photokilling efficiency due to PS aggregation in biological environments. Despite this, recent preclinical studies reported on successful combinatorial regimes of PSs with chemotherapeutics obtained through the drugs encapsulation in multifunctional nanometric delivery systems. The aim of the present review deals with the punctual description of several nanosystems designed not only with the objective of co-transporting a PS and a chemodrug for combination therapy, but also with the goal of improving the therapeutic efficacy by facing the main critical issues of both therapies (side effects, scarce tumor oxygenation and light penetration, premature drug clearance, unspecific biodistribution, etc.). Therefore, particular attention is paid to the description of bio-responsive drugs and nanoparticles (NPs), targeted nanosystems, biomimetic approaches, and upconverting NPs, including analyzing the therapeutic efficacy of the proposed photo-chemotherapeutic regimens in in vitro and in vivo cancer models.